Proteome, Inc./Incyte Genomics provides its customers, including 20 of the world’s largest pharmaceutical companies, with sophisticated protein analysis database tools that transform scientific publications into an analyzable relational database. Instead of conducting searches of the literature about, e.g. protein interaction, a scientist can access the Proteome database through a link on his or her computer. Users can be assured the data is current because the Proteome staff continually reviews the relevant literature and provides weekly updates to the database. The Proteome services are sold on an annual renewable license basis. Proteome was a pioneer in protein literature curation and developed a formidable head start against potential competitors by virtue of having reviewed and summarized 40,000 scientific articles. The company was sold to Incyte Genomics (NasdaqGM:INCY) for cash and stock with an aggregate value of $77 million. We received $16.6 million on our $4.0 million investment. The holding period was 12 months.
Location: United States, Massachusetts, Beverly
Employees: 51-200
Founded date: 1997
Investors 1
| Date | Name | Website |
| - | Boston Mil... | bostonmill... |
Mentions in press and media 3
| Date | Title | Description |
| 28.05.2020 | Human Proteome Company Nautilus Biotechnology Raises $76 Million | Nautilus Biotechnology, a company that is pioneering high-throughput and low-cost platform for analyzing and quantifying the human proteome, announced it has raised $76 million Nautilus Biotechnology, a company that is pioneering high-throu... |
| 17.12.2018 | Proteome blood test developer Seer emerges with $36M in funding | Seer, a liquid biopsy company aimed at querying the body’s proteome, has emerged from stealth with $36 million in funding to develop early-warning tests for cancer and neurological diseases. Seer employs nanotechnology, protein chemistry an... |
| 17.12.2018 | Proteome blood test developer Seer emerges with $36M in funding | Seer, a liquid biopsy company aimed at querying the body’s proteome, has emerged from stealth with $36 million in funding to develop early-warning tests for cancer and neurological diseases. Sponsored by Agilent Technologies How would you l... |